Immune Mediated Therapy for Cancer: Preclinical Assessment of Immunobiology and Combination Activity in vitro and in vivo

Tue2  Sep03:30pm(30 mins)
Charter 3
 Robert Wilkinson


Immune mediated therapies for cancer (IMT-C), such as anti-CTLA-4 and anti-PD-1/PD-L1, are showing significant promise in the treatment of solid tumors. However, although these treatments can show significant overall benefit, a subset of patients fails to respond. It is believed that activity in these patients is limited by a lack of immune priming or by immunosuppression. Combination with standard of care therapies (such as, chemo- and radiotherapy), molecular targeted therapies and or other IMT-Cs, has the potential to overcome these hurdles to response and maximize patient benefit. In order to select the best combination partners, a greater understanding is needed as to how other therapies affect the immune system both directly, through effects on leukocytes, and indirectly, through effects on tumor immunogenicity and induction of tumor cell death. Presented is a preclinical systematic approach taken towards examining the effects of combining the above modalities with IMT-Cs.

Hosted By

The European Laboratory Research & Innovation Group Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Event Logo Follow us on Twitter

Get the App

Get this event information on your mobile by
going to the appstore or google play and search for 'elrig'
Eventflo Home
copyright ELRIG,, Labhoo Ltd 2003-2021